- Home
- SOR vs ZNTL Comparison
SOR vs ZNTL Comparison
Compare SOR & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SOR | ZNTL |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 391.5M | 468.9M |
| IPO Year | 1995 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SOR | ZNTL |
|---|---|---|
| Price | $46.41 | $4.61 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $6.60 |
| AVG Volume (30 Days) | 14.2K | ★ 3.9M |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.03 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $39.82 | $1.13 |
| 52 Week High | $50.41 | $6.95 |
Technical Indicators
Market Signals| Indicator | SOR | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 53.85 | 59.28 |
| Support Level | $44.89 | $1.53 |
| Resistance Level | $47.61 | $6.95 |
| Average True Range (ATR) | 1.25 | 0.71 |
| MACD | 0.22 | 0.20 |
| Stochastic Oscillator | 69.05 | 51.33 |
Price Performance
Historical ComparisonAbout SOR Source Capital Inc.
Source Capital Inc is a diversified, closed-end management investment company. The investment objective of the company is to seek maximum total return for Common shareholders from both capital appreciation and investment income to the extent consistent with the protection of invested capital.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.